The British Journal of Cardiology

JULY 17, 2024

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease 52

Kidney Disease Outcomes Diabetes Heart Failure 52

DAIC

APRIL 6, 2024

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81